Third-party testing for peptides means an analytical laboratory with no commercial interest in the result measured the material and issued its own report — and the phrase only carries weight when the laboratory is named, the report is dated, and the report cites the lot number you can buy. Everything else marketed as third-party testing is either in-house quality control wearing a borrowed label or a genuine report for a batch that no longer exists. This guide covers who actually performs these tests, which analyses answer which questions, how a vendor-submitted sample differs from a blind-purchased one, and how to verify a report against a vial in your hand. Research use only.
Third-party testing for peptides: three tiers, only one independent
| Tier | Who performs it | Independence | What it is good for |
|---|---|---|---|
| In-house QC | The synthesiser's own analytical department | None — same organisation | Routine release; the source of most COAs |
| Contract analysis | A commercial lab paid by the vendor to test a vendor-supplied sample | Partial — independent instrument, vendor-chosen sample | Confirming the synthesiser's own numbers |
| Blind third-party | A lab testing a sample bought anonymously from normal retail stock | Full | Establishing what a buyer actually receives |
The distinction between rows two and three is the one that gets elided most often. A vendor that selects the vial it sends for testing controls the variable the test exists to measure. Independent programmes that purchase from public listings, without identifying themselves, are the only design that answers the question a buyer is actually asking. When a vendor publishes contract-lab results, that is useful corroboration of its certificate of analysis — just not proof of retail consistency.
What the tests actually measure
| Test | Question it answers | Typical method | Reported as |
|---|---|---|---|
| Purity | What fraction of the peptide-containing material is the target species? | Reversed-phase HPLC, UV at 214 nm | % of total peak area |
| Identity | Does the dominant species have the expected mass? | ESI-MS or MALDI-TOF | Observed vs theoretical Da |
| Quantity / content | How much peptide is in the vial? | Quantitative HPLC against a standard, or amino-acid analysis | mg per vial, or % net peptide content |
| Water content | How much residual moisture remains after lyophilization? | Karl Fischer titration | % w/w |
| Counter-ion | Is the salt acetate or trifluoroacetate, and how much? | Ion chromatography | % w/w |
| Endotoxin | Is bacterial lipopolysaccharide present? | LAL (gel-clot, chromogenic or turbidimetric) | EU per mg |
| Sterility / bioburden | Is viable microbial growth present? | Membrane filtration or direct inoculation, USP <71> | Pass/fail, or CFU |
| Heavy metals | Are elemental contaminants within limits? | ICP-MS | ppm or ppb per element |
| Residual solvents | Is synthesis or purification solvent left behind? | Headspace GC | ppm |
Most published third-party peptide reports run only the first three. That is a reasonable priority order — purity, identity and content answer the questions that change an experiment's result — but it means "third-party tested" almost never implies sterility or endotoxin testing, and should not be read as such.
Worked example: reading a quantity result correctly
This is the analysis most often misreported, in both directions.
- The report. A vial labelled 10 mg is assayed by quantitative HPLC at 8.6 mg of peptide. Headlines call this a 14% shortfall.
- Check the salt. Synthetic peptides are isolated as salts. An acetate salt of a peptide with several basic residues commonly carries 5–12% counter-ion by mass; residual water after lyophilization adds another 2–8%.
- Do the arithmetic. 8.6 ÷ 10 = 86% net peptide content, which sits squarely inside the normal 70–90% range. The vial is not underfilled — it contains 10 mg of powder, of which 8.6 mg is peptide, exactly as a correctly stated COA would have said.
- When it is a shortfall. If the COA claims 95% net peptide content and the independent assay returns 86%, that is a real discrepancy of 0.9 mg per vial and worth raising. The failure is the mismatch between claim and measurement, not the number itself.
- What it means downstream. Reconstituting that vial with 2 mL gives 4.3 mg/mL of peptide, not 5 mg/mL — a 14% error in every concentration derived from it, and a 14% error in molarity.
The lesson is that a quantity report is only interpretable alongside a net peptide content claim. Without one, an 8.6 mg result is ambiguous.
Verifying a report against your vial
- Match the lot. The lot number printed on the vial must appear on the report. Not the product name — the lot.
- Check the dates. The analysis date should postdate the manufacture date and precede the expiry. A report older than the lot it claims to describe is a filing error at best.
- Check the sample provenance. A report should state how the laboratory obtained the sample: submitted by the manufacturer, submitted by a distributor, or purchased. If it does not say, assume it was submitted.
- Look at the chromatogram, not the summary. Purity is an integration result. Confirm the trace is present, the gradient and column are stated, detection is at 214 nm or another justified wavelength, and the run is long enough that late-eluting impurities would have appeared. The reading method is in HPLC purity explained.
- Check identity separately. Observed mass should sit within a fraction of a dalton of theory for a small peptide. See mass spectrometry and peptide identity.
- Cross-check against the vendor COA. Two documents describing the same lot should agree within analytical variability — typically well under a percentage point on purity. A two-point gap is a question worth asking.
- For blends, expect per-component data. A single purity figure cannot describe a multi-component vial; see blends vs single vials.
What third-party testing cannot tell you
- Nothing about the next lot. Each report describes one batch. Consistency across lots is a manufacturing property that only repeated testing demonstrates.
- Nothing about stability. A purity figure at release says nothing about purity after nine months in a warm warehouse.
- Nothing about biological activity. A correct mass and a clean chromatogram do not establish that a peptide folds, binds or signals. Disulfide-bonded and cyclic peptides can be chemically correct and conformationally wrong.
- Nothing about legal status. Testing is an analytical exercise; it does not change what the material may be used for, which is covered in what research use only means.
- Nothing that a vendor cannot cherry-pick if the vendor chose the sample.
How to use this in practice
Treat an independent report as one input among several rather than as a verdict. The strongest evidence a buyer can assemble is a lot-matched vendor COA with a chromatogram and MS, a stated net peptide content, and — where available — an independent report on that same lot obtained from a blind purchase. Where the three agree, the material is well characterised. Where they disagree, the gap itself is the finding. The broader supplier evaluation sits in the vendor checklist, and further questions in the purity, COA and testing FAQ.